ODM-103 / Orion Corp - LARVOL DELTA

Orion Group financial statement release for 2014 (Orion Press Release) - "Net sales of Orion's Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs were down by 18% at EUR 169 (207) million, which was 18% (22%) of the Pharmaceuticals business's net sales."; P1, N=54; NOCIFIM (NCT01840423); P1, N=67; NOCOS (NCT01688089); Sponsor: Orion Corporation; "Orion has completed Phase I clinical safety trials with new COMT inhibitors (ODM-103 and ODM-104). Based on the results obtained, Orion has decided to select ODM-104 for further development and is preparing to commence Phase II clinical trials with the molecule."

Anticipated new P2 trial • Anticipated phase shift • Pipeline update • Sales • Trial completion • Parkinson's Disease